(Q37702149)

22 August 2017

1 reference

title

The NLRP3 inflammasome, a target for therapy in diverse disease states (English)

1 reference

22 August 2017

1 reference

2

Sinisa Savic

0 references

Michael McDermott

series ordinal

4

object named as

Michael F McDermott

0 references

Graham P. Cook

object named as

Graham P Cook

series ordinal

1

0 references

author name string

Miriam Wittmann

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

European Journal of Immunology

22 August 2017

published in

1 reference

22 August 2017

volume

40

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

631-634

1 reference

Danger signaling through the inflammasome acts as a master switch between tolerance and sensitization

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

A proposed classification of the immunological diseases

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*)

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Interleukin-1-receptor antagonist in the Muckle-Wells syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

An autoinflammatory disease due to homozygous deletion of the IL1RN locus

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Use of canakinumab in the cryopyrin-associated periodic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

A pilot study of IL-1 inhibition by anakinra in acute gout

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Successful treatment of resistant pseudogout with anakinra

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Cytokine traps: multi-component, high-affinity blockers of cytokine action

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Skin immune sentinels in health and disease

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Inflammasome components NALP 1 and 3 show distinct but separate expression profiles in human tissues suggesting a site-specific role in the inflammatory response

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Activation of the IL-1β-Processing Inflammasome Is Involved in Contact Hypersensitivity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

From innate to adaptive immune responses in contact hypersensitivity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Use of IL-18 production in a human keratinocyte cell line to discriminate contact sensitizers from irritants and low molecular weight respiratory allergens.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Mice deficient in IL-1beta manifest impaired contact hypersensitivity to trinitrochlorobenzone.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Is there a role for locally produced interleukin-1 in the deleterious effects of high glucose or the type 2 diabetes milieu to human pancreatic islets?

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Interleukin-1-receptor antagonist in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Glyburide inhibits the Cryopyrin/Nalp3 inflammasome

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Cancer-related inflammation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Inflammasomes as microbial sensors

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Thalidomide inhibits activation of caspase-1.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Interleukin-1 participates in the progression from liver injury to fibrosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Inflammasome-mediated regulation of hepatic stellate cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

NLRs at the intersection of cell death and immunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Anakinra for rheumatoid arthritis: a systematic review

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200940162

7 January 2021

Identifiers

DOI

10.1002/EJI.200940162

1 reference

22 August 2017

1 reference